Welcome to our dedicated page for Bone Biologics news (Ticker: BBLG), a resource for investors and traders seeking the latest updates and insights on Bone Biologics stock.
Bone Biologics Corp (symbol: BBLG) is a leading biotechnology firm focused on regenerative medicine orthobiologics. Originally a spin-off of the Musculoskeletal Transplant Foundation (MTF), Bone Biologics utilizes technology licensed from UCLA. The company was founded in 2004 in collaboration with professors from the University of California, Osaka University, and a USC surgeon. Acquired by MTF in 2006, MTF remains the major shareholder and primary funder.
Bone Biologics' core technology, UCB-1™, is a patented platform designed to facilitate superior bone growth. This technology has demonstrated remarkable success in large animal model studies, including sheep and rhesus monkeys, showing its capability in surpassing existing standards of care. The company believes that UCB-1™ can significantly improve outcomes in various surgical procedures involved in bone repair and regeneration.
The firm’s proprietary product, NELL-1, serves as a bone void filler and is positioned to revolutionize several surgical specialties. These include spinal surgery, general orthopedics, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. Bone Biologics is headquartered in the United States and continues to pioneer healthcare solutions aimed at enhancing bone regeneration.
With its broad applications and promising results, Bone Biologics is at the forefront of developing innovative treatments that can aid numerous medical fields. The company’s commitment to excellence and continuous improvement makes it a noteworthy player in the biotechnology sector.
Bone Biologics Corporation (NASDAQ: BBLG) has announced the approval of a multicenter pilot clinical trial for its NB1 bone graft by the Human Research Ethics Committee in Australia. The trial will enroll 30 adult patients undergoing transforaminal lumbar interbody fusion (TLIF) for degenerative disc disease (DDD). This study aims to assess the safety and effectiveness of NB1, which showed promising results in animal studies. The company aims to capture a part of the $3 billion global market for spine fusion products. Furthermore, the long-term goal includes addressing osteoporosis and trauma, potentially tapping into additional markets valued at $11 billion and $8 billion, respectively.
Bone Biologics Corporation (NASDAQ: BBLG) has engaged Avania as the Contract Research Organization (CRO) for its upcoming pilot clinical trial of NB1, targeting degenerative disc disease patients undergoing Transforaminal Lumbar Interbody Fusion (TLIF). The multicenter trial will assess the safety and effectiveness of the NB1 bone graft in 30 subjects, anticipated to start in late 2023, pending ethics committee approval from the Monash Health system in Australia. The inclusion of rhNELL-1 in the NB1 device is expected to enhance bone formation. CEO Jeffrey Frelick expressed optimism about moving into human testing with Avania's support.
Bone Biologics Corporation (NASDAQ: BBLG) has announced advancements in their lead product, NB1, utilizing NELL-1 for spinal fusion treatments. The global market for bone graft substitutes is estimated at
On October 13, 2022, WallachBeth Capital LLC announced the closure of an underwritten public offering for Bone Biologics (NASDAQ: BBLG), generating total gross proceeds of $5,100,000. The offering included 3,777,778 units at $1.35 per unit, each comprised of one share of common stock and three different Series warrants. The warrants have various exercise prices and expiration timelines, with some allowing cashless exercises. Underwriters were granted a 45-day option to purchase additional securities. The offering was made under an SEC registration statement that became effective on October 6, 2022.
Bone Biologics Corporation (NASDAQ: BBLG) has completed its underwritten public offering, raising
FAQ
What is the current stock price of Bone Biologics (BBLG)?
What is the market cap of Bone Biologics (BBLG)?
What does Bone Biologics Corp (BBLG) specialize in?
What is UCB-1™ technology?
Which surgical specialties can benefit from Bone Biologics' technologies?
When was Bone Biologics Corp founded?
Who are the primary collaborators in founding Bone Biologics?
What is NELL-1?
Who is the major shareholder and primary funder of Bone Biologics?
Where is Bone Biologics Corp headquartered?
What makes Bone Biologics' UCB-1™ technology unique?
What is the goal of Bone Biologics' research and development?
